Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03225547
Title Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago

Her2-receptor negative breast cancer

triple-receptor negative breast cancer


Mifepristone + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.